Read this Open Access paper!
MicrobiotaMi 2020 is coming!!
Milano, 1 marzo 2018 – Scoperto il “lato buono” del recettore TLR4. Normalmente responsabile dei fenomeni infiammatori, il TLR4, se opportunamente stimolato può favorire la crescita e la differenziazione delle cellule staminali neurali (NSC), attualmente in sperimentazione per una serie di malattie del sistema nervoso, come la sclerosi laterale amiotrofica (SLA) e la sclerosi multipla (SM). Lo rivela lo studio “Toll-like receptor 4 modulation influences human neural stem cell proliferation
Full Paper Co-administration of Antimicrobial Peptides (AMPs) EnhancesToll-like Receptor 4 (TLR4) Antagonist Activity of a Synthetic Glycolipid Authors Francesco Peri, Fabio Alessandro Facchini, Helena Coelho, Stefania Enza Sestito, Sandra Delgado, Alberto Minotti, David Andreu, Jesús Jiménez-Barbero ChemMedChem Abstract This study describes the effect of co-administration of antimicrobial peptides (AMPs) and synthetic glycolipid FP7, active in inhibiting inflammatory cytokine production caused by TLR4 activation and signaling. The co-administration of two
Int. J. Mol. Sci. 2017, 18(11), 2318; doi:10.3390/ijms18112318 Abstract The interactions between sugar-containing molecules from the bacteria cell wall and pattern recognition receptors (PRR) on the plasma membrane or cytosol of specialized host cells are the first molecular events required for the activation of higher animal’s immune response and inflammation. This review focuses on the role of carbohydrates of bacterial endotoxin (lipopolysaccharide, LPS, lipooligosaccharide, LOS, and lipid A), in the interaction
PhD student in chemistry at UNIMIB
TOLLerant (www.tollerant.eu) is a Marie Sklodowska-Curie Innovative Training Network (MSCA-ITN) funded by Horizon 2020 EU program and coordinated by Prof. Francesco Peri of the University of Milano Bicocca (UNIMIB). The multidisciplinary research project is focused on the study of molecular mechanisms of innate immunity, in particular Toll-like Receptors (TLR) activation and signaling and their therapeutic targeting. The network: TOLLerant consists of 8 academic and 2 industrial full partners representing 5
Florent Cochet obtained his bachelor in chemistry/biology and then his MSc degree in organic chemistry from the University Grenoble Alpes, France. During his studies he performed a first research project at the DCM (Department of Molecular Chemistry) in Grenoble, under the supervision of Dr. Sebastien Carret and Prof. François Poisson, studying the reactivity of ynol-ethers for the total synthesis of Lycorines. He completed his master thesis under the supervision of
Scientific aims: To study the role of the human TLR4 (Toll Like Receptor 4) in a number of infectious diseases including sepsis and septic shock, and inflammatory and autoimmune syndromes including neuroinflammatory and neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS (amyotrophic lateral sclerosis). TOLLerant is then aimed at molecules capable of inhibiting the TLR4. These molecules will be hit and lead compounds to develop drugs targeting diseases in which